Latest / Stock Movers / Forte Bioscience Pop; Astrazeneca Reports; Paramount-Warner Latest
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: Let's take a look at some stacks on the move today.
- 0:18Speaker 3: Let's start with the biopharma sector. There's a big winner
- 0:21Speaker 3: there this morning. Forte Biosciences ticker symbol FBRX. This is
- 0:26Speaker 3: a clinical stage biopharma company based in Dallas. It's up
- 0:30Speaker 3: thirty six percent right now. It has been on a
- 0:33Speaker 3: tear though. Guys, up one hundred percent year to date,
- 0:35Speaker 3: three hundred and seventy percent in the past year. This
- 0:38Speaker 3: is a company with a market cap of about one
- 0:40Speaker 3: point one billion dollars. It is being bought out by
- 0:43Speaker 3: the Netherlands based Rgenix for two point two billion in cash.
- 0:46Speaker 3: That's seventy seven dollars a share. Just to give you
- 0:49Speaker 3: an idea, last traded at about fifty five dollars a share.
- 0:52Speaker 3: So Fortes developing a promising drug for treating videligo and
- 0:56Speaker 3: celiac disease that they say could be used to address
- 0:59Speaker 3: multiple autoimmune conditions.
- 1:01Speaker 1: ID thing this weekend. I had no idea how big
- 1:05Speaker 1: ASML is in the Netherlands.
- 1:08Speaker 3: Oh, it's huge.
- 1:09Speaker 1: It's like ginormous. There's no American equivalent. No, it's ginormous.
- 1:14Speaker 3: They got some winners over there in the Netherlands. All right,
- 1:17Speaker 3: let's stick with medical, shall we, and go Astrozenica little
- 1:21Speaker 3: overseas there a z and is the ticker symbol up
- 1:24Speaker 3: about oh, just one percent. It has been down three
- 1:27Speaker 3: and a half percent though year to date. It reported
- 1:29Speaker 3: higher than expected profit, boosted by its blockbuster cancer medications,
- 1:33Speaker 3: earnings per share rising twenty one percent. Last quarter. The
- 1:37Speaker 3: company also released some promising results for an experimental treatment
- 1:41Speaker 3: for gastrect cancers. It now expects sales of more than
- 1:44Speaker 3: five billion dollars a year for an experimental drug for
- 1:47Speaker 3: chronic obstructive pulmonary disease. So that's stock getting a bit
- 1:52Speaker 3: of a lift today.
- 1:53Speaker 1: I look up when there's an ad on TV old
- 1:56Speaker 1: fard add we're all Diane, this will save you. I
- 1:59Speaker 1: look up with the old costs for these drugs. They're
- 2:02Speaker 1: like twenty five thou thirty thousand bucks a year, and
- 2:05Speaker 1: then it's paid by I don't know who pays for it.
- 2:08Speaker 3: It's all man grounded in mystery, and it shouldn't.
- 2:10Speaker 1: Be yeah, well said, And it comes down to, like
- 2:14Speaker 1: you pay a dollar two ninety eight, everybody else pays.
- 2:17Speaker 1: I don't know who the everybody else is, like through
- 2:19Speaker 1: through the ring, insurance or whatever. We need somebody to
- 2:21Speaker 1: come in and clear it up for us. Yes, we do.
- 2:24Speaker 3: This one was I picked this one especially for Paul Sweety.
- 2:27Speaker 3: Paramounts guidance so down just fractionally, and Warner Brothers down
- 2:32Speaker 3: one point six percent. But these two are at the altar.
- 2:35Speaker 3: They just cannot tie the knot Paramount and Warner Brothers
- 2:38Speaker 3: still tethered to one another. A federal court considering claims
- 2:42Speaker 3: that their eighty one billion dollar deal violates antitrust law.
- 2:45Speaker 3: And guess what, this case could stretch well into next year. Meanwhile,
- 2:50Speaker 3: it's going to be ticking on what Paramount owes Warner
- 2:53Speaker 3: Brothers in terms of late fees or if it ultimately
- 2:55Speaker 3: doesn't happen, there's a huge breakup fee.
- 2:57Speaker 1: Huge.
- 2:58Speaker 4: I mean the attorney for Warner Brothers, Discovery I think
- 3:01Speaker 4: did a great job here. They saw this coming potentially
- 3:04Speaker 4: maybe not from the States, but and they said, if
- 3:07Speaker 4: this happens, we're gonna get paid for this incremental reason.
- 3:10Speaker 3: So here's my question if it doesn't happen yep, Warner
- 3:13Speaker 3: Brothers gets paid richly, and then what happens who comes in,
- 3:15Speaker 3: swoops in and buys them.
- 3:17Speaker 4: No idea and who operates these companies? I'm like, how
- 3:19Speaker 4: are these companies are going to operate over the next
- 3:22Speaker 4: twelve months while this trial goes on. Are they going
- 3:24Speaker 4: to make investments?
- 3:25Speaker 1: Or twenty seconds and we'll do this longer. Is this
- 3:29Speaker 1: affected by the midterm elections?
- 3:31Speaker 4: The good news is that CNN will stay. This is
- 3:34Speaker 4: according to CNN, they will remain independent through the elections,
- 3:38Speaker 4: and for them that's important.
- 3:40Speaker 1: Okay, yep, delicate questions.
- 3:42Speaker 2: This stock Movers report from Bloomberg Radio. Check back with
- 3:46Speaker 2: us throughout the day for the latest roundup of companies
- 3:49Speaker 2: making news on Wall Street and for the latest market
- 3:52Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:57Speaker 2: Bloomberg dot com, and on Applecarplay, and and write auto
- 4:00Speaker 2: with the Bloomberg Business app. Mm hmm.